» Articles » PMID: 38002267

Neuroprotective Agents with Therapeutic Potential for COVID-19

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Nov 25
PMID 38002267
Authors
Affiliations
Soon will be listed here.
Abstract

COVID-19 patients can exhibit a wide range of clinical manifestations affecting various organs and systems. Neurological symptoms have been reported in COVID-19 patients, both during the acute phase of the illness and in cases of long-term COVID. Moderate symptoms include ageusia, anosmia, altered mental status, and cognitive impairment, and in more severe cases can manifest as ischemic cerebrovascular disease and encephalitis. In this narrative review, we delve into the reported neurological symptoms associated with COVID-19, as well as the underlying mechanisms contributing to them. These mechanisms include direct damage to neurons, inflammation, oxidative stress, and protein misfolding. We further investigate the potential of small molecules from natural products to offer neuroprotection in models of neurodegenerative diseases. Through our analysis, we discovered that flavonoids, alkaloids, terpenoids, and other natural compounds exhibit neuroprotective effects by modulating signaling pathways known to be impacted by COVID-19. Some of these compounds also directly target SARS-CoV-2 viral replication. Therefore, molecules of natural origin show promise as potential agents to prevent or mitigate nervous system damage in COVID-19 patients. Further research and the evaluation of different stages of the disease are warranted to explore their potential benefits.

Citing Articles

Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review.

Zhao Y, Tang Y, Wang Q, Li J Front Immunol. 2025; 16:1515768.

PMID: 39967658 PMC: 11832381. DOI: 10.3389/fimmu.2025.1515768.


Fast and Sensitive Detection of Anti-SARS-CoV-2 IgG Using SiO@Au@CDs Nanoparticle-Based Lateral Flow Immunoassay Strip Coupled with Miniaturized Fluorimeter.

Wang R, Xue J, Wei G, Zhang Y, Wang C, Li J Biomolecules. 2025; 14(12.

PMID: 39766275 PMC: 11673715. DOI: 10.3390/biom14121568.


Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care.

Zifko U, Guendling K, Seet R, Kasper S Front Pharmacol. 2024; 15:1338235.

PMID: 38711990 PMC: 11072190. DOI: 10.3389/fphar.2024.1338235.


Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea.

Mueller J, Muller W J Neural Transm (Vienna). 2024; 131(3):203-212.

PMID: 38347175 PMC: 10874325. DOI: 10.1007/s00702-024-02749-3.


Brain FADE syndrome: the final common pathway of chronic inflammation in neurological disease.

Hanafy K, Jovin T Front Immunol. 2024; 15:1332776.

PMID: 38304427 PMC: 10830639. DOI: 10.3389/fimmu.2024.1332776.

References
1.
Chu M, Chen X, Wang J, Guo L, Wang Q, Gao Z . Polypharmacology of Berberine Based on Multi-Target Binding Motifs. Front Pharmacol. 2018; 9:801. PMC: 6066535. DOI: 10.3389/fphar.2018.00801. View

2.
Abd El Mohsen M, Gunter Kuhnle , Rechner A, Schroeter H, Rose S, Jenner P . Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med. 2002; 33(12):1693-702. DOI: 10.1016/s0891-5849(02)01137-1. View

3.
Lundstrom K, Hromic-Jahjefendic A, Bilajac E, Aljabali A, Baralic K, Sabri N . COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. Cell Signal. 2022; 101:110495. PMC: 9568271. DOI: 10.1016/j.cellsig.2022.110495. View

4.
Bosmuller H, Matter M, Fend F, Tzankov A . The pulmonary pathology of COVID-19. Virchows Arch. 2021; 478(1):137-150. PMC: 7892326. DOI: 10.1007/s00428-021-03053-1. View

5.
Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M . Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One. 2010; 5(10):e13489. PMC: 2957444. DOI: 10.1371/journal.pone.0013489. View